Exhibit

We consent to the use of our report dated June 27, 2019, with respect to the consolidated statements of financial position of Takeda Pharmaceutical Company Limited and subsidiaries as of March 31, 2019 and 2018, and the related consolidated statements of income, other comprehensive income, change in equity, and cash flows for each of the years in the three-year period ended March 31, 2019, and the related notes, included herein and to the reference to our firm under the heading "Experts" in this registration statement on Form F-4.